AJP - Endo Journal of Neurophysiology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Endocrinol Metab 291: E1228-E1234, 2006. First published July 11, 2006; doi:10.1152/ajpendo.00171.2006
0193-1849/06 $8.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
291/6/E1228    most recent
00171.2006v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (1)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zanchi, A.
Right arrow Articles by Burnier, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zanchi, A.
Right arrow Articles by Burnier, M.

The PPAR{gamma} agonist pioglitazone modifies the vascular sodium-angiotensin II relationship in insulin-resistant rats

Anne Zanchi,1 Christine Perregaux,1 Marc Maillard,1 Daniel Cefai,1 Juerg Nussberger,2 and Michel Burnier1

1Division of Nephrology and Department of Medicine, 2Angiology Unit and Department of Medicine, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland

Submitted 8 April 2006 ; accepted in final form 6 July 2006

Glitazones are efficient insulin sensitizers that blunt the effects of angiotensin II (ANG II) in the rat. Sodium chloride is another important modulator of the systemic and renal effects of ANG II. Whether glitazones interfere with the interaction between sodium and the response to ANG II is not known. Therefore, we investigated the effects of pioglitazone on the relationship between sodium and the systemic and renal effects of ANG II in rats. Pioglitazone, or vehicle, was administered for 4 wk to 8-wk-old obese Zucker rats. Animals were fed a normal-sodium (NS) or a high-sodium (HS) diet. Intravenous glucose tolerance tests, systemic and renal hemodynamic responses to ANG II, and the renal ANG II binding and expression of ANG II type 1 (AT1) receptors were measured. The results of our study were that food intake and body weight increased, whereas blood pressure, heart rate, filtration fraction, and insulin levels decreased significantly with pioglitazone in obese rats on both diets. Pioglitazone blunted the systemic response to ANG II and abolished the increased responsiveness to ANG II induced by a HS diet. Pioglitazone modified the renal hemodynamic response to changes in salt intake while maintaining a lower filtration fraction with ANG II perfusion. These effects were associated with a decrease in the number and expression of the AT1 receptor in the kidney. In conclusion, these data demonstrate that the peroxisome proliferator-activated receptor-{gamma} agonist pioglitazone modifies the physiological relationship between sodium chloride and the response to ANG II in insulin-resistant rats.

peroxisome proliferator-activated receptor-{gamma}; glitazone; salt; blood pressure; kidney



Address for reprint requests and other correspondence: A. Zanchi, Division of Nephrology and Dept. of Medicine, Rue du Bugnon 17, CHUV, 1011 Lausanne, Switzerland (e-mail : azanchidel{at}hotmail.com)




This article has been cited by other articles:


Home page
Nephrol Dial TransplantHome page
J. Xiao, J. C. K. Leung, L. Y. Y. Chan, H. Guo, and K. N. Lai
Protective effect of peroxisome proliferator-activated receptor-gamma agonists on activated renal proximal tubular epithelial cells in IgA nephropathy
Nephrol. Dial. Transplant., July 1, 2009; 24(7): 2067 - 2077.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
A. Zanchi, A. G. Dulloo, C. Perregaux, J.-P. Montani, and M. Burnier
Telmisartan prevents the glitazone-induced weight gain without interfering with its insulin-sensitizing properties
Am J Physiol Endocrinol Metab, July 1, 2007; 293(1): E91 - E95.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2006 by the American Physiological Society.